Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Standard Biotools (LAB) Common Equity (2016 - 2025)

Historic Common Equity for Standard Biotools (LAB) over the last 17 years, with Q3 2025 value amounting to $399.7 million.

  • Standard Biotools' Common Equity fell 1832.58% to $399.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $399.7 million, marking a year-over-year decrease of 1832.58%. This contributed to the annual value of $471.7 million for FY2024, which is 41862.13% up from last year.
  • Per Standard Biotools' latest filing, its Common Equity stood at $399.7 million for Q3 2025, which was down 1832.58% from $424.5 million recorded in Q2 2025.
  • Standard Biotools' 5-year Common Equity high stood at $577.3 million for Q1 2024, and its period low was -$148.1 million during Q4 2023.
  • Moreover, its 5-year median value for Common Equity was $99.3 million (2021), whereas its average is $163.4 million.
  • Per our database at Business Quant, Standard Biotools' Common Equity crashed by 53934.79% in 2023 and then surged by 69423.38% in 2024.
  • Quarter analysis of 5 years shows Standard Biotools' Common Equity stood at $94.6 million in 2021, then tumbled by 186.12% to -$81.5 million in 2022, then crashed by 81.73% to -$148.1 million in 2023, then soared by 418.62% to $471.7 million in 2024, then fell by 15.28% to $399.7 million in 2025.
  • Its Common Equity stands at $399.7 million for Q3 2025, versus $424.5 million for Q2 2025 and $454.6 million for Q1 2025.